X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4065) 4065
Book Review (623) 623
Publication (363) 363
Magazine Article (13) 13
Book Chapter (9) 9
Conference Proceeding (4) 4
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3819) 3819
humans (2769) 2769
female (2032) 2032
male (1919) 1919
animals (1476) 1476
bisphenol a (1394) 1394
bisphenol-a (1348) 1348
benzhydryl compounds (1050) 1050
benzhydryl compounds - therapeutic use (1014) 1014
phenols - toxicity (999) 999
benzhydryl compounds - adverse effects (996) 996
adult (952) 952
middle aged (862) 862
phenols (793) 793
toxicology (759) 759
environmental sciences (748) 748
benzhydryl compounds - toxicity (657) 657
analysis (579) 579
pharmacology & pharmacy (572) 572
rats (551) 551
aged (527) 527
exposure (527) 527
pregnancy (527) 527
benzhydryl compounds - administration & dosage (524) 524
mice (516) 516
benzhydryl compounds - pharmacology (486) 486
treatment outcome (477) 477
diabetes mellitus, type 2 - drug therapy (476) 476
dose-response relationship, drug (471) 471
double-blind method (446) 446
endocrinology & metabolism (426) 426
endocrine disruptors (417) 417
double-blind (412) 412
glucosides - therapeutic use (392) 392
endocrine disruptors - toxicity (391) 391
endocrine system (356) 356
phenols - analysis (347) 347
hypoglycemic agents - therapeutic use (336) 336
adolescent (329) 329
phenols - adverse effects (327) 327
tolterodine tartrate (321) 321
type 2 diabetes (321) 321
modafinil (318) 318
estrogen (306) 306
diabetes (302) 302
research (290) 290
glucose (286) 286
abridged index medicus (283) 283
public, environmental & occupational health (282) 282
sodium-glucose transporter 2 - antagonists & inhibitors (271) 271
young adult (271) 271
glucosides - adverse effects (270) 270
in-vitro (270) 270
phenols - pharmacology (255) 255
phenols - urine (255) 255
article (254) 254
health aspects (253) 253
endocrine-disrupting chemicals (243) 243
hormones, hormone substitutes, and hormone antagonists (239) 239
urogenital system (238) 238
risk factors (236) 236
chemicals (233) 233
care and treatment (226) 226
phenols - chemistry (226) 226
dapagliflozin (225) 225
epoxy resins (223) 223
hypoglycemic agents - adverse effects (223) 223
central nervous system stimulants - therapeutic use (221) 221
efficacy (217) 217
toxicity (216) 216
child (212) 212
muscarinic antagonists - therapeutic use (212) 212
benzhydryl compounds - analysis (210) 210
time factors (209) 209
benzhydryl compounds - urine (206) 206
cresols - therapeutic use (204) 204
safety (200) 200
perinatal exposure (196) 196
bpa (194) 194
drug therapy, combination (194) 194
drug therapy (190) 190
human exposure (189) 189
risk assessment (189) 189
studies (187) 187
benzhydryl compounds - pharmacokinetics (185) 185
neurosciences (185) 185
psychiatry (183) 183
rats, sprague-dawley (183) 183
expression (182) 182
medicine, general & internal (181) 181
central nervous system stimulants - adverse effects (180) 180
overactive bladder (180) 180
benzhydryl compounds - chemistry (177) 177
environmental health (177) 177
estrogens, non-steroidal - toxicity (177) 177
gene expression (175) 175
urine (174) 174
rodents (173) 173
muscarinic antagonists - adverse effects (172) 172
glucosides - administration & dosage (171) 171
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3956) 3956
German (30) 30
Chinese (19) 19
Spanish (14) 14
French (13) 13
Japanese (13) 13
Russian (12) 12
Swedish (7) 7
Polish (4) 4
Czech (3) 3
Danish (3) 3
Bulgarian (2) 2
Italian (2) 2
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 4, pp. 323 - 334
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 22, pp. 2117 - 2128
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 384 - 393
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2014, Volume 37, Issue 3, pp. 740 - 750
Journal Article